A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults

Key Inclusion Criteria: 1. Has a SARS-CoV-2 negative test result from a sample collected ≤72 hours prior to randomization as described in the protocol 2. Has received complete primary series of standard-of-care COVID-19 vaccination per local guidance, completed at least 2 weeks prior to screening 3. Has a body mass index (BMI) between 18 and 31 Kg/m\^2 (inclusive) at the screening visit 4. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiogram (ECG)s performed at screening and/or prior to administration of initial dose of study drug Key Exclusion Criteria: 1. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, infectious, autoimmune, oncologic, psychiatric or neurological disease, as assessed by the investigator as described in the protocol 2. Presents any concern to the investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study 3. Was hospitalized (ie, \>24 hours) for any reason within 30 days of the screening visit 4. Has history of alcohol or drug abuse as determined by the investigator 5. Has a history of significant multiple and/or severe allergies (eg, latex gloves), or has had an anaphylactic reaction to prescription or non-prescription drugs or food NOTE: Other protocol defined inclusion / exclusion criteria apply